Vivoryon Therapeutics N.V. 0R3M.L Stock
Vivoryon Therapeutics N.V. Price Chart
Vivoryon Therapeutics N.V. 0R3M.L Financial and Trading Overview
| Vivoryon Therapeutics N.V. stock price | 0.49 EUR |
| Previous Close | 13.83 EUR |
| Open | 13.7 EUR |
| Bid | 0 EUR x 0 |
| Ask | 0 EUR x 0 |
| Day's Range | 13.7 - 14.16 EUR |
| 52 Week Range | 6.74 - 19.4 EUR |
| Volume | 4.28K EUR |
| Avg. Volume | 5.13K EUR |
| Market Cap | 1.85M EUR |
| Beta (5Y Monthly) | 1.532183 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.633 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
0R3M.L Valuation Measures
| Enterprise Value | 307.68M EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 12.872726 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -10.593 |
Trading Information
Vivoryon Therapeutics N.V. Stock Price History
| Beta (5Y Monthly) | 1.532183 |
| 52-Week Change | 91.09% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 19.4 EUR |
| 52 Week Low | 6.74 EUR |
| 50-Day Moving Average | 14.87 EUR |
| 200-Day Moving Average | 12.12 EUR |
0R3M.L Share Statistics
| Avg. Volume (3 month) | 5.13K EUR |
| Avg. Daily Volume (10-Days) | 5.01K EUR |
| Shares Outstanding | 8.21M |
| Float | 15.57M |
| Short Ratio | N/A |
| % Held by Insiders | 33.49% |
| % Held by Institutions | 34.10% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -65.10% |
| Return on Equity (ttm) | -130.76% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -29044000 EUR |
| Net Income Avi to Common (ttm) | -28156000 EUR |
| Diluted EPS (ttm) | -0.633 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 26.56M EUR |
| Total Cash Per Share (mrq) | 1.1 EUR |
| Total Debt (mrq) | 132K EUR |
| Total Debt/Equity (mrq) | 0.5 EUR |
| Current Ratio (mrq) | 9.401 |
| Book Value Per Share (mrq) | 1.1 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -21794000 EUR |
| Levered Free Cash Flow (ttm) | -14933625 EUR |
Profile of Vivoryon Therapeutics N.V.
| Country | United Kingdom |
| State | N/A |
| City | Halle |
| Address | Weinbergweg 22 |
| ZIP | 06120 |
| Phone | 49 345 555 9900 |
| Website | https://www.vivoryon.com |
| Industry | |
| Sector(s) | |
| Full Time Employees | 15 |
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease. In addition, the company is developing a monoclonal antibody PBD-C06 is for N3pE-Abeta. Vivoryon Therapeutics N.V. has a collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.
Q&A For Vivoryon Therapeutics N.V. Stock
What is a current 0R3M.L stock price?
Vivoryon Therapeutics N.V. 0R3M.L stock price today per share is 0.49 EUR.
How to purchase Vivoryon Therapeutics N.V. stock?
You can buy 0R3M.L shares on the LSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Vivoryon Therapeutics N.V.?
The stock symbol or ticker of Vivoryon Therapeutics N.V. is 0R3M.L.
How many shares does Vivoryon Therapeutics N.V. have in circulation?
The max supply of Vivoryon Therapeutics N.V. shares is 130.6K.
What is Vivoryon Therapeutics N.V. Price to Earnings Ratio (PE Ratio)?
Vivoryon Therapeutics N.V. PE Ratio is now.
What was Vivoryon Therapeutics N.V. earnings per share over the trailing 12 months (TTM)?
Vivoryon Therapeutics N.V. EPS is -0.633 EUR over the trailing 12 months.